Eligible participants were randomly allocated in a 1:1 ratio to either antepartum prophylactic dose dalteparin ( 5000 international units once daily up to 20 weeks ' gestation , and twice daily thereafter until at least 37 weeks ' gestation ) or to no antepartum dalteparin ( control group ) .